Raporlar

A more difficult year ahead

More brick-and-mortar retailers will leave the market

More difficult market conditions after robust growth in 2021

More insolvencies expected in 2022

High inflation and lower consumer confidence weigh on sales

Profit margins should remain stable, but downside risks remain

Retailers´ profit margins sustained by fiscal support

Decreasing profit margins for brick-and-mortar retailers

Reviving Latin America's energy transition requires wind and solar

Russia's invasion of Ukraine throws sand in the wheels of the global economy.

As government support after the pandemic is phased out, insolvencies in most markets are projected to increase in 2022 and 2023.

Chinese economic growth slows down amid several downside risks

Covid-19 vaccine production and aging populations drive growth for pharmaceuticals industry

Robust growth expected in 2022

A vast market with growing sales opportunities

Robust output growth expected in 2022

Large backlog of medical treatments to sustain growth in the coming years

Healthy profit margins despite public pressure to lower sales prices

Growing share of generics could affect local producers

Increase in production of primary products planned to lower reliance on China